RBC Capital Maintains Stryker at Outperform, Cuts Target to $375
RBC Capital maintained its Outperform rating and lowered its price target on Stryker to $375 from $420.
RBC Capital maintained its Outperform rating and lowered its price target on Stryker to $375 from $420.